Lilly's Foundayo And Lower-Dose Zepbound Helped People Maintain Weight Loss After Switching From Higher Doses Of Injectable Incretin Therapy In Two Late-Phase Trials

In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average after one year In ATTAIN-MAINTAIN and SURMOUNT-MAI ...Read more